ArticleInternational journal of fertility & sterility2026
Serotype Prevalence of Group B
Article in International journal of fertility & sterility, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Group B Materials and Methods: A systematic search was conducted in MEDLINE (via PubMed), Embase, Web of Science, and the Iranian Databases (SID and Magiran) for studies published between January 2000 and March 2023. Studies were included if they used standardized methods for GBS detection, including recto-vaginal specimen collection and identification [selective media and molecular detection of GBS-specific gene ( Results: Of 330 articles identified, 14 studies met the inclusion criteria. The meta-analyses showed that 93.2% (95% CI: 90-95.5) of GBS isolates had identifiable serotypes. The predominant serotype was serotype III [39.6% (95% CI: 31.6-48.2)], followed by serotypes II [16.8% (95% CI: 13.8-20.4)], V [14.1% (95% CI: 11.2-17.6)], VI [12.4 (95% CI: 8.2-18.5)], Ia [11.7% (95 CI: 7.8-17.2)] and Ib [11.2 (95% CI: 6.9-17.6)]. Conclusion: Serotype III is the most common GBS serotype among pregnant women in Iran, followed by serotypes II, V, VI, Ia, and Ib. These findings suggest that a pentavalent vaccine targeting these serotypes could be beneficial for preventing GBS-related complications in Iranian pregnant women. However, further research is needed to evaluate the efficacy and implementation of such a vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.